Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab.

Cheng C, Gallagher EM, Yeh JY, Earl MA.

Anticancer Drugs. 2014 Sep;25(8):964-9. doi: 10.1097/CAD.0000000000000115.

PMID:
24743519
2.

Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.

Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, Szabo Z, Jaeger U.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):297-305. doi: 10.1016/j.clml.2012.06.004.

PMID:
23040435
3.

Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.

Balducci L, Mo M, Abella E, Saven A.

Am J Clin Oncol. 2014 Dec;37(6):603-10. doi: 10.1097/COC.0000000000000141.

PMID:
25350463
4.

Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.

Langeberg WJ, Siozon CC, Page JH, Morrow PK, Chia VM.

Support Care Cancer. 2014 Aug;22(8):2167-75. doi: 10.1007/s00520-014-2184-5. Epub 2014 Mar 21.

PMID:
24652049
5.

Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.

Shin HJ, Chung JS, Song MK, Kim SK, Choe S, Cho GJ.

Cancer Chemother Pharmacol. 2012 May;69(5):1165-72. doi: 10.1007/s00280-011-1814-6. Epub 2012 Jan 4.

PMID:
22215473
6.

Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS.

J Korean Med Sci. 2014 Nov;29(11):1493-500. doi: 10.3346/jkms.2014.29.11.1493. Epub 2014 Nov 4.

7.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.

Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.

PMID:
25042202
8.

Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy.

Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS.

J Manag Care Pharm. 2003 Mar-Apr;9(2 Suppl):15-21.

9.

Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.

Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y.

Cancer. 1994 Oct 1;74(7):1939-44.

PMID:
7521788
10.

Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support.

Cabanillas F, Cotto M, Liboy I, Rivera E, Pavia OA, Bruno M.

Leuk Lymphoma. 2012 Oct;53(10):1929-33. doi: 10.3109/10428194.2012.679264. Epub 2012 Apr 23.

PMID:
22448918
11.
12.

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.

Lyman G, Lalla A, Barron R, Dubois RW.

Curr Med Res Opin. 2009 Feb;25(2):401-11. doi: 10.1185/03007990802636817 .

PMID:
19192985
13.

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma.

Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, D├╝hrsen U, Rossi FG, Schwenkglenks M, Bendall K, Szabo Z, Jaeger U.

Support Care Cancer. 2012 Mar;20(3):647-52. doi: 10.1007/s00520-011-1306-6. Epub 2011 Nov 20. Erratum in: Support Care Cancer. 2013 Feb;21(2):653. Johnson, Hans E [corrected to Johnsen, Hans E].

14.
16.

A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.

Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I.

Clin Colorectal Cancer. 2010 Apr;9(2):95-101. doi: 10.3816/CCC.2010.n.013.

PMID:
20378503
17.

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.

Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J.

Curr Med Res Opin. 2011 Jan;27(1):79-86. doi: 10.1185/03007995.2010.536527. Epub 2010 Nov 22.

PMID:
21091127
18.

Supplemental Content

Support Center